Imperative Care Initiates ADAPT 2.0 Study of Zoom System for Acute Ischemic Stroke

April 14, 2026—Imperative Care announced that the initial patients have been enrolled in the ADAPT 2.0 clinical study of continuous dual aspiration using the company’s Zoom system for acute ischemic stroke.

According to the company, the prospective, multicenter, open-label, observational study is evaluating the effectiveness, safety, and clinical outcomes of the ADAPT 2.0 technique for first-line continuous dual-aspiration thrombectomy with the Zoom system to treat stroke patients.

The ADAPT 2.0 study is expected to enroll up to 750 patients at up to 50 sites in the United States. Follow-up will be conducted for 90 days post procedure to understand both procedural and longer-term outcomes.

Imperative Care stated that the study will assess both effectiveness and safety using established clinical endpoints:

• The primary efficacy endpoint is the proportion of patients achieving excellent reperfusion (modified thrombolysis in cerebral infarction, ≥ 2c) after treatment with the Zoom stroke system, as adjudicated by an independent core-lab.
• The primary safety endpoint is the rate of embolization to new territory.

The company advised that the study is co-led by national Principal Investigators David Fiorella, MD; Shahram Majidi, MD; Justin Mascitelli, MD; and Max Mokin, MD.

“This study is designed to further examine the potential clinical benefits of the ADAPT 2.0 technique, enabled by the Zoom stroke system, to achieve reperfusion success, along with reduced time to final reperfusion—which are important indicators of long-term patient outcomes,” commented Dr. Fiorella in Imperative Care’s press release. “Recent research found that procedure time may be a stronger predictor of clinical outcomes than first pass effect.”

Dr. Fiorella continued, “Through this study, we aim to generate rigorous, real-world, independently adjudicated data on the effectiveness and safety of a systems approach in stroke care. Ultimately, our goal is to advance techniques and technologies that meaningfully improve care for patients affected by acute ischemic stroke.”